Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease. (CHANGAN)
Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Listed as NCT02874287, this PHASE4 trial focuses on Coronary Artery Disease and remains completed. Sponsored by First Affiliated Hospital Xi'an Jiaotong University, it has been updated 9 times since 2017, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2019 [monthly]
Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital Xi'an Jiaotong University
For direct contact, visit the study record on ClinicalTrials.gov .